Cart
sales@molnova.com
Darenzepine
CAS No. 84629-61-8
Darenzepine( —— )
Catalog No. M32876 CAS No. 84629-61-8
Darenzepine is a muscarinic receptor inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 472 | In Stock |
|
| 5MG | 427 | In Stock |
|
| 10MG | 599 | In Stock |
|
| 25MG | 889 | In Stock |
|
| 50MG | 1163 | In Stock |
|
| 100MG | 1572 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDarenzepine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDarenzepine is a muscarinic receptor inhibitor.
-
DescriptionDarenzepine is a muscarinic receptor inhibitor extracted from patent US 20170095465 A1.
-
In VitroDarenzepine is a muscarinic receptor inhibitor which is useful for the treatment of CNS disorders.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetAChR
-
RecptorAChR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number84629-61-8
-
Formula Weight347.41
-
Molecular FormulaC21H21N3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(\C(=O)N1CCN(C)CC1)=C/2\C=3C(C(=O)NC=4C2=CC=CC4)=CC=CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Eric Elenko, et al. Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation. US 20170095465 A1.
molnova catalog
related products
-
Mitotan
Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.
-
4-DAMP
4-DAMP (4-DAMP methiodide) is a selective muscarinic M1 and M3 subtype receptor antagonist used in the study of allergic rhinitis and cardiovascular disease.
-
9-Cyclopentyladenine
9-Cyclopentyladenine (NSC-19486) is an adenylate cyclase inhibitor that blocks cellular morphological differentiation and phosphorylation of specific signaling molecules.
